Carlo Salvarani1, Gene G Hunder, Jonathan M Morris, Robert D Brown, Teresa Christianson, Caterina Giannini. 1. From the Unità Operativa di Reumatologia (C.S.), Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy; and Anatomic Pathology, Department of Laboratory Medicine and Pathology (C.G.), Departments of Radiology (J.M.M.) and Neurology (R.D.B.), and Divisions of Biostatistics (T.C.) and Rheumatology (G.G.H.), Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To analyze the clinical findings, response to therapy, and outcomes of patients with cerebral vascular amyloid-β (Aβ) deposition with and without inflammatory vascular infiltration. METHODS: We report 78 consecutive patients with cerebral vascular Aβ deposition examined at Mayo Clinic Rochester over 25 years (1987 through 2011). Specimens reviewed by a neuropathologist showed 40 with vascular Aβ peptide without inflammation (cerebral amyloid angiopathy [CAA]), 28 with granulomatous vasculitis (Aβ-related angiitis or ABRA), and 10 with perivascular CAA-related inflammation. We also matched findings in 118 consecutive patients with primary CNS vasculitis (PCNSV) without Aβ seen over 25 years (1983 through 2007). RESULTS: Compared to the 40 with CAA, the 28 with ABRA were younger at diagnosis (p = 0.05), had less altered cognition (p = 0.02), fewer neurologic deficits (p = 0.02), and fewer intracranial hemorrhages (<0.001), but increased gadolinium leptomeningeal enhancement (p = 0.01) at presentation, and less mortality and disability at last follow-up (p < 0.001). Compared with PCNSV, the 28 patients with ABRA were older at diagnosis (p < 0.001), had a higher frequency of altered cognition (p = 0.05), seizures/spells (p = 0.006), gadolinium leptomeningeal enhancement (p < 0.001), and intracerebral hemorrhage (p = 0.02), lower frequency of hemiparesis (p = 0.01), visual symptoms (p = 0.04), and MRI evidence of cerebral infarction (p = 0.003), but higher CSF protein levels (p = 0.03). Results of treatment and outcomes in ABRA and PCNSV were similar. CONCLUSIONS: ABRA appears to represent a distinct subset of PCNSV.
OBJECTIVE: To analyze the clinical findings, response to therapy, and outcomes of patients with cerebral vascular amyloid-β (Aβ) deposition with and without inflammatory vascular infiltration. METHODS: We report 78 consecutive patients with cerebral vascular Aβ deposition examined at Mayo Clinic Rochester over 25 years (1987 through 2011). Specimens reviewed by a neuropathologist showed 40 with vascular Aβ peptide without inflammation (cerebral amyloid angiopathy [CAA]), 28 with granulomatous vasculitis (Aβ-related angiitis or ABRA), and 10 with perivascular CAA-related inflammation. We also matched findings in 118 consecutive patients with primary CNS vasculitis (PCNSV) without Aβ seen over 25 years (1983 through 2007). RESULTS: Compared to the 40 with CAA, the 28 with ABRA were younger at diagnosis (p = 0.05), had less altered cognition (p = 0.02), fewer neurologic deficits (p = 0.02), and fewer intracranial hemorrhages (<0.001), but increased gadolinium leptomeningeal enhancement (p = 0.01) at presentation, and less mortality and disability at last follow-up (p < 0.001). Compared with PCNSV, the 28 patients with ABRA were older at diagnosis (p < 0.001), had a higher frequency of altered cognition (p = 0.05), seizures/spells (p = 0.006), gadolinium leptomeningeal enhancement (p < 0.001), and intracerebral hemorrhage (p = 0.02), lower frequency of hemiparesis (p = 0.01), visual symptoms (p = 0.04), and MRI evidence of cerebral infarction (p = 0.003), but higher CSF protein levels (p = 0.03). Results of treatment and outcomes in ABRA and PCNSV were similar. CONCLUSIONS:ABRA appears to represent a distinct subset of PCNSV.
Authors: Neil J Scolding; Fady Joseph; Patricia A Kirby; Ingrid Mazanti; Françoise Gray; Jacqueline Mikol; David Ellison; David A Hilton; Timothy L Williams; James M MacKenzie; John H Xuereb; Seth Love Journal: Brain Date: 2005-01-19 Impact factor: 13.501
Authors: J C DiFrancesco; M Brioschi; L Brighina; C Ruffmann; E Saracchi; G Costantino; G Galimberti; E Conti; N A Curtò; L Marzorati; P Remida; F Tagliavini; M Savoiardo; C Ferrarese Journal: Neurology Date: 2011-03-01 Impact factor: 9.910
Authors: Carlo Salvarani; Robert D Brown; Kenneth T Calamia; Teresa J H Christianson; John Huston; James F Meschia; Caterina Giannini; Dylan V Miller; Gene G Hunder Journal: Arthritis Rheum Date: 2011-11
Authors: Carlo Salvarani; Robert D Brown; Kenneth T Calamia; Teresa J H Christianson; Stephen D Weigand; Dylan V Miller; Caterina Giannini; James F Meschia; John Huston; Gene G Hunder Journal: Ann Neurol Date: 2007-11 Impact factor: 10.422
Authors: C Salvarani; R D Brown; K T Calamia; T J H Christianson; J Huston; J F Meschia; C Giannini; D V Miller; G G Hunder Journal: Rheumatology (Oxford) Date: 2008-08-27 Impact factor: 7.580
Authors: Reisa Sperling; Stephen Salloway; David J Brooks; Donatella Tampieri; Jerome Barakos; Nick C Fox; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Ivan Lieberburg; H Michael Arrighi; Kristen A Morris; Yuan Lu; Enchi Liu; Keith M Gregg; H Robert Brashear; Gene G Kinney; Ronald Black; Michael Grundman Journal: Lancet Neurol Date: 2012-02-03 Impact factor: 44.182
Authors: Michelle M Miller-Thomas; Adam L Sipe; Tammie L S Benzinger; Jonathan McConathy; Sarah Connolly; Katherine E Schwetye Journal: Radiographics Date: 2016 Jul-Aug Impact factor: 5.333
Authors: S Suthiphosuwan; A Bharatha; C C-T Hsu; A W Lin; J A Maloney; D G Munoz; C A Palmer; A G Osborn Journal: AJNR Am J Neuroradiol Date: 2020-09-03 Impact factor: 3.825